Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Combogesic IV (acetaminophen & ibuprofen) is a opioid-free pain relief medicine. It is approved by USFDA for use in adults for relief of mild to moderate pain & the management of moderate to severe pain as an adjunct to opioid analgesics.
Lead Product(s): Paracetamol,Ibuprofen
Therapeutic Area: Neurology Product Name: Combogesic
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Hyloris Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 27, 2024
Details:
Combogesic IV (acetaminophen & ibuprofen) is a opioid-free pain relief medicine. It is approved by USFDA for use in adults for relief of mild to moderate pain & the management of moderate to severe pain as an adjunct to opioid analgesics.
Lead Product(s): Paracetamol,Ibuprofen
Therapeutic Area: Neurology Product Name: Combogesic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 05, 2024
Details:
Under the agreement, Hikma gains right for MAb-B43.13 (oregovomab), a murine monoclonal antibody, being tested in combination with carboplatin and paclitaxel for patients with advanced ovarian cancer, in the Middle East and North Africa (MENA) region.
Lead Product(s): Oregovomab,Paclitaxel,Carboplatin
Therapeutic Area: Oncology Product Name: MAb-B43.13
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: CanariaBio
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement October 10, 2023
Details:
Under the terms of the agreement, Hikma will have priority rights for the commercialisation and manufacture of SK Biopharmaceuticals’ current and future pipeline of innovative products for 17 countries in the MENA region.
Lead Product(s): Cenobamate
Therapeutic Area: Neurology Product Name: Xcopri
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: SK Biopharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement August 21, 2023
Details:
Under the terms of the agreement, Hikma has an exclusive license to commercialize products in Rakuten Medical's pipeline using its photoimmunotherapy technology platform, Alluminox™, in all its MENA markets.
Lead Product(s): Cetuximab Sarotalocan Sodium
Therapeutic Area: Oncology Product Name: ASP-1929
Highest Development Status: Phase IIIProduct Type: Large molecule
Recipient: Rakuten Medical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement August 10, 2023
Details:
Dobutamine injection stimulates heart muscle and improves blood flow by helping the heart pump better, which is used short-term to treat cardiac decompensation due to weakened heart muscle.
Lead Product(s): Dobutamine Hydrochloride
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Dobutamine-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 14, 2023
Details:
Tuoyi (toripalimab) is an anti-PD-1 monoclonal antibody developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, and for enhanced receptor internalization (endocytosis function).
Lead Product(s): Toripalimab
Therapeutic Area: Oncology Product Name: Tuoyi
Highest Development Status: ApprovedProduct Type: Large molecule
Recipient: Shanghai Junshi Biosciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement December 26, 2022
Details:
The efficacy and safety of RYALTRIS (olopatadine hydrochloride) was established in a robust clinical studies program in over 4,000 patients with SAR. Twice-daily RYALTRIS™ provided statistically significant improvement in both nasal and ocular symptoms vs placebo.
Lead Product(s): Olopatadine Hydrochloride,Mometasone Furoate
Therapeutic Area: Immunology Product Name: Ryaltris
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 30, 2022
Details:
The combination with Custopharm enhances Hikma’s R&D capabilities and pipeline and expands Hikma’s differentiated US portfolio to close to 130 commercialised injectable medicines – a more than fivefold increase over the last decade, including Acetaminophen injection.
Lead Product(s): Paracetamol
Therapeutic Area: Neurology Product Name: Acetaminophen-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Custopharm
Deal Size: $425.0 million Upfront Cash: $375.0 million
Deal Type: Acquisition April 21, 2022
Details:
The acquisition marks Hikma’s expansion into Canada and a portfolio of 25 sterile injectable products including the marketed product Atropine-G, three in-licenced ophthalmic products and a pipeline of seven additional products, four of which are approved by Health Canada.
Lead Product(s): Atropine
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Atropine-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Teligent, Inc
Deal Size: $45.8 million Upfront Cash: Undisclosed
Deal Type: Acquisition January 17, 2022